Molecular targeting in radiotherapy: Epidermal growth factor receptor

Molecular Interventions

Volumn 5, Issue 1, 2005, Pages 15-19

  Chung, Theodore D ^a   Broaddus, William C ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH FACTOR; CANERTINIB; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; IMMUNOMODULATING AGENT; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RADIOISOTOPE; RADIOPROTECTIVE AGENT; RADIOSENSITIZING AGENT; TOXIN; TRANSFORMING GROWTH FACTOR ALPHA; TYRPHOSTIN;

BREAST CANCER; CANCER INHIBITION; CANCER RADIOTHERAPY; ENZYME INHIBITION; GENE TARGETING; GENE TRANSFER; GLIOBLASTOMA; IONIZING RADIATION; LIGAND BINDING; LUNG SMALL CELL CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; HUMANS; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RADIATION TOLERANCE; RADIATION, IONIZING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 16344375866     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.5.1.5     Document Type: Review

References (19)

1. Jemal, A., Tiwari, R.C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E.J., and Thun, M.J. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29 (2004).
2. Yarden, Y. and Slikowski, M.X. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2, 127-137 (2001). A review of the ErbB pathways.
3. Pedersen, M.W., Meltorn, M., Damstrup, L. et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann. Oncol. 12, 745-760 (2001).
4. Lammering, G., Hewit, T.H., Hawkins, W.T. et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J. Natl. Cancer Inst. 93, 921-929 (2001).
5. Schmidt-Ullrich R.K., Mikkelsen, R.B., Dent, P. et al. Radiation induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 1191-1197 (1997).
6. Todd, D.G., Mikkelsen, R.B., Rorrer, W.K., Valerie, K., and Schmidt-Ullrich, R.K. Ionizing radiation stimulates existing signal transduction pathways involving the activation of epidermal growth factor receptor and ERBB-3 and changes of intracellular calcium in A431 human squamous carcinoma cells. J. Recept. Signal Transduct. Res. 19 885-908 (1999).
7. Lammering, G., Hewit, T.H., Valerie, K., Contessa, J.N., Amorino, G.P., Dent, P., and Schmidt-Ullrich, R.K. EGFRvIII-mediate radioresistance through a strong cytoprotective response. Oncogene 22, 5545-5553. (2003).
8. Herbst, R.S. and Hong, W.K. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head & neck cancer. Semin. Oncol. 29(Suppl. 14), 18-30 (2002).
9. Kim, E.S., Mauer, A.M., Fossella, F.V. et al. A phase II study Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel chemotherapy refractory/resistant patients with advanced nonsmall cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 21, 293a (2002).
10. Karashima, T., Sweeney, P., Slaton, J.W. et al. Inhibition of angiogenesis by the anti-epidermal growth factor receptor antibody, Imclone C225 in androgen independent prostate cancer growing orthotopically in nude mice. Clin. Cancer Res. 8, 1253-1264 (2002).
11. Bonner, J.A., Raish, K.P., Trummell, H.Q. et al. Enhanced apoptosis with combination C225/radiation serves as impetus for clinical investigation in head and neck cancers. J. Clin. Oncol. 18, 47S-53S (2000).
12. Ciardiello, F., Caputo, R., Bianco, R. et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cell by ZD-1839 (Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053-2063 (2002).
13. Huang, S.-M., Li, J., Armstrong, E.A. et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 62 4300-4306 (2002).
14. Rao, G.S., Murray, S., and Ethier, S.P. Radiosenstization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 48, 1519-1528 (2000).
15. Spivak-Kroizman, T., Rotin, D., Pincahsi, D., Ullrich, A., Schlessinger, J., and Lax, I. Heterodimerization of c-cerbB2 with different epidermal growth factor receptor mutants elicit stimulatory or inhibitory responses. J. Biol. Chem. 267, 8056-8063 (1992).
16. Lammering, G., Hewit, T.H., Valerie, K., Lin, P.S., Contessa, J.N., and Schmidt-Ullrich, R.K. Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. Int. J. Radiat. Biol. 79, 561-568 (2003).
17. Contessa, J.N., Reardon, D.B., Todd, D. et al. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin. Cancer Res. 5, 405-411 (1999).
18. Lammering, G., Hewit, T.H., Holmes, M., Valerie, K., Hawkins, W., Lin, P.S., Mikkelsen, R.B., and Schmidt-Ullrich, R.K. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin. Cancer Res. 10, 6732-6743 (2004).
19. Broaddus, W.C., Gillies, G.T., and Kucharczyk, J. Minimally invasive procedures. Advances in image-guided delivery of drug and cell therapies into the central nervous system. Truwit, C.L. (ed): Neuroimaging Clinics of North America: MR-Guided Therapy in Neurosurgery. Vol. 11(4), pp. 727-735, (2001).